Letter to the Editor: Development of possible COVID-19 vaccine for elderly

Siukan LAW, Albert Wingnang LEUNG, Chuanshan XU

Research output: Other PublicationsOther ArticleResearch

Abstract

According to the Centers for Disease Control and Prevention in the USA, reported that the risk of infection with COVID-19 increases with age, especially in older adults, and those who suffered from other immune diseases or continuously taking medications. Some elderly are immunosenescence due to the decline in an immune system’s functionality with age, thus, the COVID-19 vaccine may not be effective for them and it is big trouble. How does the COVID-19 vaccine induce robust immune responses in the elderly?
In general, the number of naive T cells decreases while age increases. This makes the B cells lose their function and less attachment on the antibodies surface lead unable to defend and target the virus for destruction causing it cannot engulf the virus and nor cause inflammation to remove the infected cells. Therefore, it is not easy to develop a suitable COVID-19 for the elderly.
Pawelec et al. indicated that it must have a biomarker in the elderly COVID-19 vaccine. There is an investigation of the Yellow Fever vaccination.
Original languageEnglish
Specialist publicationMicrobes and Infectious Diseases
DOIs
Publication statusE-pub ahead of print - 16 Nov 2020

Keywords

  • COVID-19 vaccine
  • Elderly
  • Robust immune responses

Fingerprint Dive into the research topics of 'Letter to the Editor: Development of possible COVID-19 vaccine for elderly'. Together they form a unique fingerprint.

Cite this